Abstract
The enzyme xanthine oxidoreductase (XOR) catalyzes the last two steps of purine catabolism in the highest uricotelic primates. XOR is an enzyme with dehydrogenase activity that, in mammals, may be converted into oxidase activity under a variety of pathophysiologic conditions. XOR activity is highly regulated at the transcriptional and post-translational levels and may generate reactive oxygen and nitrogen species, which trigger different consequences, ranging from cytotoxicity to inflammation. The low specificity for substrates allows XOR to metabolize a number of endogenous metabolites and a variety of exogenous compounds, including drugs.
The present review focuses on the role of XOR as a drug-metabolizing enzyme, specifically for drugs with anticancer, antimicrobial, antiviral, immunosuppressive or vasodilator activities, as well as drugs acting on metabolism or inducing XOR expression.
XOR has an activating role that is essential to the pharmacological action of quinone drugs, cyadox, antiviral nucleoside analogues, allopurinol, nitrate and nitrite. XOR activity has a degradation function toward thiopurine nucleotides, pyrazinoic acid, methylxanthines and tolbutamide, whose half-life may be prolonged by the use of XOR inhibitors.
In conclusion, to avoid potential drug interaction risks, such as a toxic excess of drug bioavailability or a loss of drug efficacy, caution is suggested in the use of XOR inhibitors, as in the case of hyperuricemic patients affected by gout or tumor lysis syndrome, when it is necessary to simultaneously administer therapeutic substances that are activated or degraded by the drug-metabolizing activity of XOR.
Keywords: Anticancer drugs, Antimicrobial drugs, Immunosuppressive drugs, Nitrovasodilators, Purine analogues, Xanthine oxidoreductase.
Current Medicinal Chemistry
Title:Xanthine Oxidoreductase in Drug Metabolism: Beyond a Role as a Detoxifying Enzyme
Volume: 23 Issue: 35
Author(s): Maria Giulia Battelli, Letizia Polito, Massimo Bortolotti and Andrea Bolognesi
Affiliation:
Keywords: Anticancer drugs, Antimicrobial drugs, Immunosuppressive drugs, Nitrovasodilators, Purine analogues, Xanthine oxidoreductase.
Abstract: The enzyme xanthine oxidoreductase (XOR) catalyzes the last two steps of purine catabolism in the highest uricotelic primates. XOR is an enzyme with dehydrogenase activity that, in mammals, may be converted into oxidase activity under a variety of pathophysiologic conditions. XOR activity is highly regulated at the transcriptional and post-translational levels and may generate reactive oxygen and nitrogen species, which trigger different consequences, ranging from cytotoxicity to inflammation. The low specificity for substrates allows XOR to metabolize a number of endogenous metabolites and a variety of exogenous compounds, including drugs.
The present review focuses on the role of XOR as a drug-metabolizing enzyme, specifically for drugs with anticancer, antimicrobial, antiviral, immunosuppressive or vasodilator activities, as well as drugs acting on metabolism or inducing XOR expression.
XOR has an activating role that is essential to the pharmacological action of quinone drugs, cyadox, antiviral nucleoside analogues, allopurinol, nitrate and nitrite. XOR activity has a degradation function toward thiopurine nucleotides, pyrazinoic acid, methylxanthines and tolbutamide, whose half-life may be prolonged by the use of XOR inhibitors.
In conclusion, to avoid potential drug interaction risks, such as a toxic excess of drug bioavailability or a loss of drug efficacy, caution is suggested in the use of XOR inhibitors, as in the case of hyperuricemic patients affected by gout or tumor lysis syndrome, when it is necessary to simultaneously administer therapeutic substances that are activated or degraded by the drug-metabolizing activity of XOR.
Export Options
About this article
Cite this article as:
Battelli Giulia Maria, Polito Letizia, Bortolotti Massimo and Bolognesi Andrea, Xanthine Oxidoreductase in Drug Metabolism: Beyond a Role as a Detoxifying Enzyme, Current Medicinal Chemistry 2016; 23 (35) . https://dx.doi.org/10.2174/0929867323666160725091915
DOI https://dx.doi.org/10.2174/0929867323666160725091915 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lymphocyte Homing to the Liver
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Fighting Type-2 Diabetes: Present and Future Perspectives
Current Medicinal Chemistry CCR2 Antagonists
Current Topics in Medicinal Chemistry The Application of Mechanical Aerosol Delivery Systems in an in vitro Model of Mechanically Ventilated Neonates
Recent Patents on Drug Delivery & Formulation Subject Index To Volume 2
Current Cardiology Reviews Modulation of the Rho/ROCK Pathway in Heart and Lung after Thorax Irradiation Reveals Targets to Improve Normal Tissue Toxicity
Current Drug Targets The Role of Hypocarbia in the Development of Cystic Periventricular Leukomalacia
Current Pediatric Reviews Gene Therapy for the Prevention of Ischemia / Reperfusion Injury in Organ Transplantation
Current Gene Therapy New Vectors and Strategies for Cardiovascular Gene Therapy
Current Gene Therapy Recent Advances in Transcranial Focused Ultrasound (FUS) Triggered Brain Delivery
Current Drug Targets Pulmonary Arterial Hypertension
Current Vascular Pharmacology Wound Healing Activity of Hydro-alcoholic Extract of Cinnamomum nitidum Blume (Lauraceae) in Wistar Albino Rats
Current Traditional Medicine Pulmonary Arterial Hypertension in Connective Tissue Diseases
Current Respiratory Medicine Reviews The Angiotensin Converting Enzyme 2 (ACE2), Gut Microbiota, and Cardiovascular Health
Protein & Peptide Letters Extracellular RNA, a Potential Drug Target for Alleviating Atherosclerosis, Ischemia/Reperfusion Injury and Organ Transplantation
Current Pharmaceutical Biotechnology Low-Dose Aspirin-Associated Upper and Mid Gastrointestinal Tract Damage and Gene Polymorphism
Current Pharmaceutical Design Cardiac Metabolism in Myocardial Ischemia
Current Pharmaceutical Design Ghrelin and Motilin in the Gastrointestinal System
Current Pharmaceutical Design Gene Therapy as a Novel Pharmaceutical Intervention for Stroke
Current Pharmaceutical Design The Role of αA-Crystallin in Experimental Autoimmune Uveitis
Current Molecular Medicine